Overview

Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures

Status:
Terminated

Trial end date:
2019-06-10

Target enrollment:

Participant gender:

Summary

The primary purpose of this study is to assess the long-term safety and tolerability of Cannabidiol Oral Solution (CBD) in pediatric participants with treatment-resistant childhood absence seizures.

Phase:

Phase 2

Details

Lead Sponsor:

Benuvia Therapeutics Inc.
INSYS Therapeutics Inc

Treatments:

Cannabidiol
Pharmaceutical Solutions